The results showed that the anti-MSLN-sP CAR-T cells were better able to attack target cancer cells (Figure 3C) and penetrate through the HA-containing matrix than conventional anti-MSLN CAR-T cells (Figures 3D, E). The gene discussed is TFF2; the disease is cancer.